XFOR — X4 Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $33.00m
- $6.36m
- $2.56m
Annual cashflow statement for X4 Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -62.1 | -88.7 | -93.9 | -101 | -37.5 |
| Depreciation | |||||
| Non-Cash Items | 7.03 | 18.8 | 10.5 | 3.89 | -96.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.06 | -1.5 | 5.74 | 0.344 | 2.67 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -58.8 | -70.9 | -77.1 | -96.5 | -131 |
| Capital Expenditures | -1.36 | -0.615 | -0.103 | -0.06 | -7.33 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | 0 | — | -14.8 | 74.3 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Cash from Investing Activities | -1.36 | -0.615 | -0.103 | -14.9 | 67 |
| Financing Cash Flow Items | -0.278 | 0 | -4.81 | -0.631 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 12.4 | 74.2 | 117 | 88.5 | 20.3 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -47.4 | 2.41 | 39.9 | -22.8 | -43.8 |